Multi-marker report synthesis
A typical consumer microbiome PDF might show low diversity, a dysbiosis flag, low Faecalibacterium, high Akkermansia, a low butyrate pathway score, and a narrative to increase prebiotics, all on one page. Those lines are not a coherent diagnosis. They are different measurement layers (ecology, inference, marketing copy) compressed into one dashboard.
This page teaches triangulation: how to weigh markers, resolve conflicts, and decide what (if anything) to act on, without a single “gut health score.”
Start with Reading your microbiome report for routing; use this page when two or more lines contradict each other or your symptoms do not match the report story.
The synthesis workflow (four steps)
Step 1, Anchor on symptoms and clinical context
| Ask first | Why |
|---|---|
| What is the main symptom (bloating, constipation, diarrhoea, pain)? | Routes to symptom synthesis pages |
| Any red flags (blood, weight loss, nocturnal symptoms)? | Clinical care first, not microbiome-first |
| Calprotectin or other clinical tests available? | Inflammation layer beats sequencing scores (Gut inflammation markers) |
| Recent antibiotics, PPIs, major diet change, probiotic? | Explains large snapshot shifts (Medications, Post-antibiotic recovery) |
Symptom-first rule: If the report says “optimize microbiome” but you are asymptomatic, the default action is usually observe or repeat later, not supplement stacks. If you are symptomatic, treat the report as hypothesis-generating, not a prescription.
Step 2, Assign each line item a reliability tier
Not all numbers on the page deserve equal weight.
| Tier | Examples | Weight in synthesis |
|---|---|---|
| A, Clinical biomarkers | Fecal calprotectin, pathogen PCR where indicated | Highest for inflammation/infection questions |
| B, Established taxa (method-appropriate) | F. prausnitzii, Bifidobacterium, Akkermansia on shotgun; genus on 16S with caution | Moderate, association literature, weak individual diagnosis |
| C, Community summaries | Alpha diversity, beta diversity, enterotype labels | Moderate-low, context-dependent (Alpha diversity) |
| D, Proprietary indexes | ”Gut health score,” dysbiosis index, sequencing inflammation score, pathway abundance | Lowest, often undisclosed algorithms (Dysbiosis, Metagenomic pathway scores) |
| E, Narrative recommendations | ”Take probiotic X,” “avoid all FODMAPs” | Not evidence unless linked to strain-specific trials |
When tiers conflict, higher tier wins for that question. Example: normal calprotectin + high sequencing inflammation score → prioritize calprotectin and clinical assessment; treat the sequencing flag as unvalidated for your decision.
Step 3, Separate geography, function, and abundance
Reports often merge three different ideas:
| Layer | What it is | Common report lines |
|---|---|---|
| Who (taxonomy) | Relative abundance of taxa | Akkermansia, Roseburia, opportunistic lists |
| Inferred function | Gene/pathway counts | Butyrate production score, β-glucuronidase |
| Where (implicit) | Stool ≈ colon lumen | Cannot infer SIBO, mucosal disease, pelvic floor |
A low butyrate pathway score with detectable Roseburia is not always a contradiction, pathway inference ≠ measured butyrate (SCFAs, Metagenomic pathway scores). Methanogen reads in stool ≠ methane breath test (SIBO page).
Step 4, Resolve conflicts; pick one primary hypothesis
Choose one leading hypothesis aligned with symptoms and tier-A/B data. Park other flags as monitor or retest, see Retesting over time.
Reliability hierarchy (quick reference)
Clinical biomarkers (calprotectin)
↓
Validated symptom-directed tests (breath testing when clinically indicated)
↓
Shotgun taxa / diversity (same lab, repeated samples)
↓
16S genus-level calls
↓
Proprietary scores & single-timepoint "optimal ranges"Cross-study meta-analyses show technical variation (extraction, region, platform) can bias diversity and composition as much as some biological effects (Lozupone et al., 2013 meta-analysis). Within-person microbiomes are often more stable than between-person comparisons at a given time (HMP 2012; Franzosa et al., 2019).
Common conflicting patterns, and how to read them
1. Low Faecalibacterium prausnitzii + high Akkermansia muciniphila
Why it looks contradictory: Both are labeled “beneficial” on many panels; one is low, one high, so the report may imply partial failure.
Ecological reality: They occupy different niches (mucus-associated degrader vs luminal butyrate producer) and can coexist, with cross-feeding from mucin degradation supporting butyrate producers in research models (Belzer et al., 2017; Lopez-Siles et al., 2018).
| Do | Don’t |
|---|---|
| Read each species page on its own evidence | Treat as a seesaw where one must go down for the other to go up |
| Ask if fiber/FODMAP context explains F. prausnitzii (Dietary fiber) | Buy separate “boost Faecalibacterium” and “boost Akkermansia” stacks by default |
| Consider shotgun vs 16S resolution for both calls | Panic about “conflicting good bacteria” |
If symptomatic with constipation: high Akkermansia alone does not rule out slow transit or methane, see Constipation. If bloated: do not assume low F. prausnitzii means add inulin, see Chronic bloating.
2. “Dysbiosis detected” + normal calprotectin + IBS-type symptoms
Resolution: Likely functional gut pathway, not IBD flare.
| Weight more | Weight less |
|---|---|
| Symptom pattern → FODMAPs, motility, bloating synthesis | Vendor dysbiosis index as diagnosis |
| Normal calprotectin for inflammation screen | Low diversity alone as proof of illness |
“Dysbiosis” on reports is not standardized (Dysbiosis; Hooks & O’Malley, 2017). IBS cohorts show inconsistent alpha diversity changes (Duvallet et al., 2017).
3. Low alpha diversity + several “beneficial” taxa in range
Why it happens: Diversity counts evenness and richness across all detected taxa, you can have adequate key genera but many rare taxa missing, or depth/method effects (Alpha diversity).
Resolution: Do not treat as emergency. Ask:
- Post-antibiotic or recent illness?
- Same lab as a prior sample for trend?
- Are symptoms actually changed?
4. Low butyrate pathway score + normal Roseburia / Faecalibacterium
Resolution: Pathway inference ≠ measured SCFA output. Database annotation, gene depth, and unassembled pathways limit scores (Metagenomic pathway scores). Taxa presence is tier B; pathway score is tier D unless independently validated.
If asymptomatic: usually no action. If symptomatic: fiber type and tolerance matter more than pathway percentage (SCFAs).
5. High “inflammation score” (sequencing) + normal calprotectin
Resolution: Treat sequencing inflammation indexes as tier D for clinical decisions (Gut inflammation markers, Sequencing inflammation score). Low F. prausnitzii is an IBD association, not a substitute for calprotectin.
Escalate clinical workup on symptoms and calprotectin, not on vendor inflammation flags alone.
6. Opportunistic bacteria flagged + no symptoms + no immunosuppression
Resolution: Many panels flag Proteobacteria, Klebsiella, Candida by deviation from reference, not infection (Opportunistic bacteria). Post-antibiotic blooms are common (Klebsiella context).
| Consider escalation if | Usually observe if |
|---|---|
| Fever, bloody diarrhoea, immunocompromise | Mild GI symptoms only |
| Rising calprotectin | Single snapshot flag |
7. Report says “increase fiber/prebiotics” + you bloat on current diet
Resolution: Symptom trumps report narrative. Fermentable substrate load may exceed tolerance (Chronic bloating, FODMAPs). Sequence:
- Map FODMAP load / identify trigger fibers
- Stabilize symptoms
- Gradual fiber reintroduction (High-fiber diet)
Do not add inulin + probiotic + polyphenol simultaneously, Supplement stack interactions.
8. High Bifidobacterium after starting a probiotic + “still dysbiotic”
Resolution: Probiotic strains may appear in stool without lasting colonization or symptom benefit (Probiotics & prebiotics). The detected increase may be the product itself. Compare pre-probiotic baseline if the question is “did it work?” (Retesting).
Symptom-first vs report-first (decision table)
| Situation | Lead with |
|---|---|
| Clear IBS bloating after meals | Bloating synthesis → FODMAP / SIBO / motility branches |
| Constipation-predominant | Constipation → fiber vs methane vs pelvic floor |
| Report-only anxiety, minimal symptoms | Education + optional retest; avoid stacks |
| Inflammatory symptoms | Calprotectin / clinical pathway before taxa tuning |
| Post-antibiotic snapshot | Post-antibiotic recovery; expect low diversity temporarily |
Worked examples (outline)
Example A, IBS bloating, low diversity, low F. prausnitzii, high Akkermansia
- Symptom anchor: bloating after onion/wheat meals → FODMAP hypothesis (Bloating).
- Tier: ignore dysbiosis score for now; species calls tier B.
- Conflict: low F. prausnitzii + high Akkermansia → not mutually exclusive; no dual-target supplement required.
- Action frame: dietitian-supervised low-FODMAP trial (strong IBS evidence) before prebiotics.
- Retest: only if changing diet long-term and same lab.
Example B, Asymptomatic, “severe dysbiosis,” low diversity
- Symptom anchor: none → report is descriptive only.
- Tier: dysbiosis/diversity tier C/D.
- Context: recent travel or antibiotics? If yes, expect transient shift.
- Action frame: no supplement stack; repeat sample months later if curious (Retesting).
- Avoid: interpreting as pre-disease without clinical correlation (Rinninella et al., 2019).
Example C, Diarrhoea, high sequencing inflammation score, normal calprotectin
- Symptom anchor: diarrhoea → infection, IBD, IBS-D, bile acid malabsorption workup clinically.
- Tier: calprotectin A beats inflammation score D.
- Microbiome role: secondary; may show diversity ↓ in diarrhoea cohorts (Duvallet).
- Action frame: clinical stool tests first; microbiome optional.
Example D, Constipation, Methanobrevibacter detected on stool, negative breath test
- Geography conflict: stool methanogen read ≠ IMO/SIBO diagnosis.
- Symptom anchor: constipation → motility/methane branch (Motility).
- Action frame: breath testing interpretation with clinician; do not treat stool archaea percentage alone.
Context checklist (before changing diet or supplements)
- Antibiotics in last 3–6 months?
- Current PPI, metformin, GLP-1, opioids? (Medications)
- Active low-FODMAP or high-fiber experiment?
- Probiotic in last 2–4 weeks (may appear on report)?
- Same lab and method as any prior sample?
- Sample type stool vs saliva (Sample types)
What not to do with a conflicting report
| Trap | Better approach |
|---|---|
| Treat every red/yellow flag as urgent | Tier markers; symptom-first routing |
| Average conflicting advice into a mega-stack | One hypothesis → one intervention window |
| Assume taxa are good-vs-bad pairs | Read ecology and species pages |
| Let pathway scores override food tolerance | Symptoms + diet trials |
| Ignore calprotectin because the report “looks inflammatory” | Gut inflammation markers |